{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2019-05-22&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest&answer.answeringMemberPrinted=Andrew%20Stephenson", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-date=2019-05-22&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest&answer.answeringMemberPrinted=Andrew%20Stephenson", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2019-05-22&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest&_metadata=all&answer.answeringMemberPrinted=Andrew%20Stephenson", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2019-05-22&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest&answer.answeringMemberPrinted=Andrew%20Stephenson", "isPartOf" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2019-05-22&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest&answer.answeringMemberPrinted=Andrew%20Stephenson", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-date=2019-05-22&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest&answer.answeringMemberPrinted=Andrew%20Stephenson", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2019-05-22&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest&answer.answeringMemberPrinted=Andrew%20Stephenson", "type" : "http://purl.org/linked-data/api/vocab#ListEndpoint"} , "items" : [{"_about" : "http://data.parliament.uk/resources/1698103", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698103/answer", "answerText" : {"_value" : "
Cutting waiting lists is one of the Prime Minister\u2019s top priorities. To reduce the National Health Service\u2019s waitlist, the Department plans to spend more than £8 billion from 2022/23 to 2024/25. This funding will expand capacity by creating a new network of community diagnostic centres, and maximising all available independent sector capacity. In addition, we are managing demand through specialised advice in primary care, and giving patients more control over where they receive their care.<\/p>
To reduce waiting times for elective surgeries specifically, we are transforming the way the NHS provides elective surgeries, by increasing activity through dedicated and protected surgical hubs. £1.5 billion of funding has been awarded for the development of new surgical hubs and the expansion of surgical hub sites, as well as increased bed capacity and equipment, to help elective services recover. The hubs will focus on providing high volume low complexity surgery, as recommended by the Royal College of Surgeons of England. There are currently 100 elective surgical hubs that are operational across England, as of March 2024. These surgical hubs help to separate elective care facilities from urgent and emergency care.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-03-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-03-28T13:30:06.493Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Surgery: Wellingborough"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce waiting time for elective surgeries for people in Wellingborough constituency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/5011", "label" : {"_value" : "Biography information for Gen Kitchen"} } , "tablingMemberConstituency" : {"_value" : "Wellingborough"} , "tablingMemberPrinted" : [{"_value" : "Gen Kitchen"} ], "uin" : "20125"} , {"_about" : "http://data.parliament.uk/resources/1698124", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698124/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence\u2019s guidance on semaglutide, the active ingredient in wegovy, for managing overweight and obesity was published in March 2023, and updated in September 2023. It recommends semaglutide as a treatment option for patients that meet specified eligibility criteria, and recommends that the treatment is provided within specialist weight management services. These services are typically provided in secondary rather than primary care settings. The Government is committed to the safe introduction of new weight loss drugs into the National Health Service, and is exploring ways to increase access to more people, who meet the relevant eligibility criteria.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-03-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-03-28T13:23:44.997Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-03-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Obesity: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress NHS England has made on integrating Wegovy to existing weight management structures within primary care settings.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"} } , "tablingMemberConstituency" : {"_value" : "North Tyneside"} , "tablingMemberPrinted" : [{"_value" : "Mary Glindon"} ], "uin" : "20056"} , {"_about" : "http://data.parliament.uk/resources/1697887", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1697887/answer", "answerText" : {"_value" : "
There were 10,558 community pharmacies in England on 29 February 2024, including 405 distance selling pharmacies. These contractors are independent private businesses contracted to provide services within the National Health Service. While the Department does not monitor their stock levels, it does have a role in managing supply at a national level to help ensure stocks are available from manufacturers to meet demand from patients across the country. We are often made aware of supply issues. Thankfully the vast majority can be managed with no impact to patients.<\/p>
We work with the industry, the NHS, the Medicines and Healthcare products Regulatory Agency and others working across the supply chain to manage issues and we provide guidance for health care professionals about medicines that are experiencing supply issues on how to manage patients during a disruption where necessary.<\/p>
The Medicine Supply Tool is designed to provide information and guidance for healthcare professionals, rather than members of the public. However, a public-facing page on attention deficit hyperactivity disorder medicine supply is available at the following link:<\/p>
https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/<\/a><\/p> Any patient who is worried about the supply of their medication should speak to their clinician, in the first instance.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "19916"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-26T15:22:10.277Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Attention Deficit Hyperactivity Disorder: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to give patients access to information on stock levels of ADHD medication at high street pharmacies; and whether her Department has made an assessment of the potential merits of giving patients access to the Medicines Supply Tool.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4510", "label" : {"_value" : "Biography information for Helen Hayes"}
}
, "tablingMemberConstituency" : {"_value" : "Dulwich and West Norwood"}
, "tablingMemberPrinted" : [{"_value" : "Helen Hayes"}
], "uin" : "19915"}
, {"_about" : "http://data.parliament.uk/resources/1697888", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1697888/answer", "answerText" : {"_value" : " There were 10,558 community pharmacies in England on 29 February 2024, including 405 distance selling pharmacies. These contractors are independent private businesses contracted to provide services within the National Health Service. While the Department does not monitor their stock levels, it does have a role in managing supply at a national level to help ensure stocks are available from manufacturers to meet demand from patients across the country. We are often made aware of supply issues. Thankfully the vast majority can be managed with no impact to patients.<\/p> We work with the industry, the NHS, the Medicines and Healthcare products Regulatory Agency and others working across the supply chain to manage issues and we provide guidance for health care professionals about medicines that are experiencing supply issues on how to manage patients during a disruption where necessary.<\/p> The Medicine Supply Tool is designed to provide information and guidance for healthcare professionals, rather than members of the public. However, a public-facing page on attention deficit hyperactivity disorder medicine supply is available at the following link:<\/p> https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/<\/a><\/p> Any patient who is worried about the supply of their medication should speak to their clinician, in the first instance.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "19915"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-26T15:22:10.32Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Attention Deficit Hyperactivity Disorder: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment she has made of the availability of information about stock levels of ADHD medication by high street pharmacies; and what steps is she taking to help ensure patients can identify pharmacies with stocks of their prescription.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4510", "label" : {"_value" : "Biography information for Helen Hayes"}
}
, "tablingMemberConstituency" : {"_value" : "Dulwich and West Norwood"}
, "tablingMemberPrinted" : [{"_value" : "Helen Hayes"}
], "uin" : "19916"}
, {"_about" : "http://data.parliament.uk/resources/1697892", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1697892/answer", "answerText" : {"_value" : " The Medicines and Healthcare products Regulatory Agency (MHRA) works in collaboration with a number of enforcement and regulatory agencies to share intelligence, support strategic planning, produce guidance, and review emerging issues. There is no legal requirement for Trading Standards to share seizure data with the MHRA, however this data is shared in cases where the MHRA can provide evidence to support ongoing compliance and enforcement investigations.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-26T15:38:03.597Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Electronic Cigarettes and Tobacco"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether trading standards officers are required to share information on seized non-compliant (a) tobacco and (b) vaping products with the Medicines and Healthcare products Regulatory Agency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4603", "label" : {"_value" : "Biography information for Preet Kaur Gill"}
}
, "tablingMemberConstituency" : {"_value" : "Birmingham, Edgbaston"}
, "tablingMemberPrinted" : [{"_value" : "Preet Kaur Gill"}
], "uin" : "19919"}
, {"_about" : "http://data.parliament.uk/resources/1697901", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1697901/answer", "answerText" : {"_value" : " Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities. The National Health Service is improving cancer pathways to get people diagnosed faster once referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 113 NSS pathways are currently operational, with more in development.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-28T11:38:14.567Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Ovarian Cancer: Diagnosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce regional variations in early diagnosis of ovarian cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4638", "label" : {"_value" : "Biography information for Mr Tanmanjeet Singh Dhesi"}
}
, "tablingMemberConstituency" : {"_value" : "Slough"}
, "tablingMemberPrinted" : [{"_value" : "Mr Tanmanjeet Singh Dhesi"}
], "uin" : "19931"}
, {"_about" : "http://data.parliament.uk/resources/1697942", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1697942/answer", "answerText" : {"_value" : " We\u2019re working hard to support research, and provide the best possible care to those living with sickle cell disease (SCD) across the country. The Department funds health and care research through the National Institute for Health and Care Research (NIHR). Over the past five financial years, the NIHR has invested more than £8 million in funding and support for SCD research.<\/p> NHS Blood and Transplant (NHSBT) is the largest provider of apheresis services, a blood transfusion used to treat SCD. NHSBT will be delivering projects over the next 12 months that will increase both nursing capacity and the physical space in which apheresis occurs. We are also working to increase Ro subtype blood donation numbers, the blood type used to treat SCD, identify opportunities to improve clinical pathways, and deliver world-leading treatments, such as the new blood matching genetic test announced by NHS England earlier this year, which will reduce the risk of side effects and offer more personalised care.<\/p> NHS England\u2019s Chief Executive Officer has committed to improving the treatment and outcomes of patients with SCD, and has commissioned a Sickle Cell Pathway Quality Improvement work package. A quality improvement review of existing processes has led to a range of improvements including awareness, education, and training of both patients and professionals.<\/p> The National Healthcare Inequalities Improvement Programme (HiQiP) has recently introduced a number of initiatives as part of the wider aim of tackling inequalities for people living with SCD. This includes: piloting of urgent and emergency department bypass units in London and Manchester, which will ensure people with SCD with an uncomplicated vaso-occlusive crisis are assessed and given pain relief in a timely manner; the provision of a credit card sized Sickle Cell Alert Card to all people with SCD, to alert medical and clinical staff that the carrier is a registered SCD patient and that they should be managed as a medical emergency; a London wide commissioning for the design and upload of a patient care record onto an interoperable digital platform which, when fully operational, will give clinicians and medical personnel in different regions access to a patient\u2019s personalised care and analgesia record, removing ambiguity on effective treatment; and several products to support the above, including a communications campaign to raise awareness of existing NHS England arrangements to support people with SCD to save money on the costs of regular prescriptions, as well as the Can you tell it's Sickle Cell campaign and an e-learning module, both from NHS England. Further information on the Can you tell it's Sickle Cell campaign and the e-learning module is available respectively, at the following links:<\/p> https://www.england.nhs.uk/2022/06/nhs-launches-lifesaving-sickle-cell-campaign/<\/a><\/p>